Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: The PHENOMENAL phase 2 study


Por: Borrego, MR, Lopez-Bravo, DP, Vila, MM, Pérez-García, JM, Fernández, M, Tormo, SB, García-Saenz, JA, Lema, L, Garau, I, Cortez, P, Torres, AA, Conejo, EA, Calvo, I, Ferrer, N, Blancas, I, Amillano, K, Santasusagna, S, Benderra, MA, Alcalá-Lopez, D, Antonarelli, G, Sampayo-Cordero, M, Llombart-Cussac, A and Cortés, J

Publicada: 17 ene 2026 Ahead of Print: 1 dic 2025
Resumen:
Introduction Patients with breast cancer (BC) and brain metastases (BMs) have a poor prognosis, particularly those with human epidermal growth factor 2-negative (HER2[-]) BC, including hormone receptor-positive (HR[+]) and triple-negative breast cancer (TNBC). Liposomal irinotecan (nal-IRI) crosses the blood-brain barrier and enhances antitumor activity. Methods PHENOMENAL (NCT03328884) was a single-arm, open-label, multicenter phase 2a study in Spain. Eligible patients had HER2[-] BC with active or stable BMs and prior chemotherapy regimen for metastatic disease (>= 1 taxane line required). Nal-IRI was administered intravenously at 60 mg/m(2) (salt-base) or 50 mg/m(2) (free-base) every 14 days until progression and/or unacceptable toxicity. The primary endpoint was intracranial objective response rate (IC-ORR) in patients with progressive BMs. Key secondary endpoints included ORR, clinical benefit rate (CBR), progression-free survival (PFS), overall survival (OS), and safety. Results Fifty-six women (median age 52 years; range, 32-83) were enrolled across 16 sites. Of these, 51.8 % had TNBC, and 91.1 % had progressive BMs at baseline. Median follow-up was 5.7 months (range, 0.4-56.5). The trial achieved its primary endpoint, with IC-ORR of 22.0 % (95 % CI, 11.5-36.0; p < 0.001) among patients with progressive BMs. Median PFS was 1.5 months (95 % CI, 1.4-2.9), while median OS reached 6.4 months (95 % CI, 4.9-10.8). Treatment-emergent adverse events (TEAEs) occurred in 96.4 % of patients; 57.1 % were considered treatment-related and 14.3 % experienced grade >= 3 treatment-related events. Only one patient had a serious treatment-related event, and no treatment-related deaths occurred. Conclusions nal-IRI demonstrated IC activity in HER2[-] BC with BMs. While overall efficacy was limited and long-term outcomes remain poor, these results highlight the unmet need in this challenging population and support the importance of developing more treatment strategies.

Filiaciones:
Borrego, MR:
 Hosp Virgen Rocio, Seville, Spain

Lopez-Bravo, DP:
 Med Scientia Innovat Res MEDSIR, Barcelona, Spain

 Med Scientia Innovat Res MEDSIR, Ridgewood, NJ 07450 USA

 Hosp Santa Creu i St Pau, Oncol Dept, Barcelona, Spain

:
 Germans Trias i Pujol Res Inst, Catalan Inst Oncol, Inst Catala Oncol, Med Oncol Serv,B ARGO Res Grp, Carretera Canyet S-N, Badalona 08916, Spain

Pérez-García, JM:
 Med Scientia Innovat Res MEDSIR, Barcelona, Spain

 Med Scientia Innovat Res MEDSIR, Ridgewood, NJ 07450 USA

 Int Breast Canc Ctr IBCC, Quiron Grp, Pangaea Oncol, Barcelona, Spain

Fernández, M:
 Univ Alcala Henares, Hosp Univ Ramon y Cajal, Madrid, Spain

Tormo, SB:
 Inst Valenciano Oncol, Valencia, Spain

García-Saenz, JA:
 Hosp Univ Clin San Carlos, Madrid, Spain

Lema, L:
 Hosp Univ 12 Octubre, Med Oncol, Madrid, Spain

Garau, I:
 Hosp Son Llatzer, Palma De Mallorca, Spain

Cortez, P:
 Univ Europea, Hosp Ruber Juan Bravo, Madrid, Spain

Torres, AA:
 Hosp Univ Miguel Servet, Zaragoza, Spain

Conejo, EA:
 Hosp Clin Univ Virgen Victoria, Malaga, Spain

Calvo, I:
 MD Anderson Canc Ctr, Breast Canc Unit Oncol, Madrid, Spain

 Fdn MD Anderson Int Espana, Madrid, Spain

Ferrer, N:
 Hosp Univ Son Espases, Palma De Mallorca, Spain

Blancas, I:
 Granada Univ, San Cecilio Univ Hosp, Dept Med, Granada, Spain

 Inst Invest Biosanit IBS, Granada, Spain

Amillano, K:
 Hosp Univ St Joan Reus, Med Oncol Dept, Reus, Spain

Santasusagna, S:
 Med Scientia Innovat Res MEDSIR, Barcelona, Spain

 Med Scientia Innovat Res MEDSIR, Ridgewood, NJ 07450 USA

Benderra, MA:
 Med Scientia Innovat Res MEDSIR, Barcelona, Spain

 Med Scientia Innovat Res MEDSIR, Ridgewood, NJ 07450 USA

Alcalá-Lopez, D:
 Med Scientia Innovat Res MEDSIR, Barcelona, Spain

 Med Scientia Innovat Res MEDSIR, Ridgewood, NJ 07450 USA

Antonarelli, G:
 Natl Canc Inst IRCCS, European Inst Oncol, Div New Drugs & Early Drug Dev Innovat Therapies, Milan, Italy

 Univ Milan, Dept Oncol & Hemato Oncol DIPO, Milan, Italy

Sampayo-Cordero, M:
 Med Scientia Innovat Res MEDSIR, Barcelona, Spain

 Med Scientia Innovat Res MEDSIR, Ridgewood, NJ 07450 USA

Llombart-Cussac, A:
 Med Scientia Innovat Res MEDSIR, Barcelona, Spain

 Med Scientia Innovat Res MEDSIR, Ridgewood, NJ 07450 USA

 Hosp Arnau Vilanova, FISABIO, Valencia, Spain

 Univ Cardenal Herrera CEU, Fac Ciencias Salud, Dept Med, Translat Oncol Grp, Alfara Del Patriarca, Spain

Cortés, J:
 Med Scientia Innovat Res MEDSIR, Barcelona, Spain

 Med Scientia Innovat Res MEDSIR, Ridgewood, NJ 07450 USA

 Int Breast Canc Ctr IBCC, Quiron Grp, Pangaea Oncol, Barcelona, Spain

 Univ Europea Madrid, Fac Biomed & Hlth Sci, Dept Med, Madrid, Spain

 Hosp Beata Maria Ana, IOB Madrid, Madrid, Spain

 Hosp Univ Torrejon, Oncol Dept, Ribera Grp, Madrid, Spain
ISSN: 09598049





European Journal of Cancer
Editorial
Elsevier Ltd., THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 233 Número:
Páginas: 116161-116161
WOS Id: 001640950400001
ID de PubMed: 41371050

MÉTRICAS